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MDiscussion
Dr Nevin Katz (Baltimore, Md). This is an important report.
This study addresses the important clinical issue of thrombocyto-
penia, which is not unusual in this current era of cardiac surgery in
patients who have undergone complex cardiac surgery or who
have ongoing infection or multiorgan system dysfunction
postoperatively. The results of IVIG in your patients is impressive.
My first question regards the limitation of the study that you
have recognized, and you mentioned that it is a nonrandomized
study. There is no control group.
During the study period, did you encounter patients who
developed postoperative thrombocytopenia of less than 60,000
but did not choose to receive the IVIG. If you did, could you
comment on the courses of their platelet counts, and if present,
the courses of their respiratory, renal, and infectious issues?
Dr Rankin. I am troubled by the limitations of randomized
trials, and I have been involved with many of them over the years.
They are good for some things, and studies that involve drugs
usually require randomized trials for on-label approval. ThereThe Journal of Thoracic and Cahave been many randomized trials using IVIG to modulate im-
mune thrombocytopenia, and they all have been positive. It works.
In regard to nontreated patients, I did not have anyone who
refused IVIG during this period. I was thinking, as you were talk-
ing, back to 1970, and my internship at Alabama (your former
institution). At that time, I saw my first patient whose toes turned
black after mitral valve surgery, associated with thrombocytopenia
and multiorgan failure. So this disorder has been around for a
while, and it has been one of the most frustrating problems that
we encounter.
Then in the 1980s, Chuck Greenberg and Jim Lowe’s first
publication on heparin-associated thrombocytopenia thrombosis
syndrome had 2 of my patients in it from Duke, and we would
see this problem not infrequently in that era and since. So I have
had a lot of experience with this syndrome over the years, and I
have to say that since 2002 and institution of the IVIG protocol,
it has been a relief to have zero patients with major complications
from it. IVIG has been effective in every single patient
experiencing a rapidly decreasing platelet count and immune
dysfunction. Sometimes it takes several days to turn around, and
I have 3 patients now in whom plasmapheresis was used in a
complementary fashion in the first few days of therapy.
I am not sure that, at this point, a randomized trial would be
ethical, given all the previous data with IVIG and immune
thrombocytopenia. Indications are that the surgical variety is just
another form of immune dysfunction like all the medical forms.
The immune moiety, or inappropriate autoantibody, probably is
going to be different. We need to explore that in basic
immunologic research. I think it is clear that this problem is
immune-mediated, and modulation with IVIG seems safe and
extremely effective in the surgical setting.
Dr Katz. My second question has to do with the mechanism,
and I think it is one of the important points of this report is detailing
the various causes that could explain this. Because many people
have thought that if the PF4 antibody test is negative, then it is
not ‘‘HIT.’’ So it is important to look at the mechanism.
Now, the fact that all but 1 patient in your series underwent
valve or aortic surgery raises the question whether the decreased
platelet counts were related to mechanical trauma to the platelets
by passage of blood through the cardiotomy suction system of
the pump oxygenator. I am wondering if you consider trauma
related to heart-lung machines as a factor, and can you relate
that to the immunologic mechanism?
Dr Rankin. It is unclear exactly what is going on there. If we
look at our larger series of immune dysfunction, the factors that
are common to these patients includeworse baseline profiles, older
sicker people, and longer pump runs. Pre-existing immune
disorders, such as rheumatoid arthritis or lupus, also are common.
But it is mostly patients with complex valves, multiple valves in
the elderly population, and so on, who get this syndrome. In a
quick 1-hour pump run or 1.5-hour pump run for a coronary
bypass, it is less common.
I believe it is more related to the duration of cardiopulmonary
bypass and the degree of dysregulation of the immune system. Since
we have been obtaining IgG levels postoperatively, the majority of
these patients have low postoperative IgG levels. Sometimes, it will
be 200 or 300 with a lower limit of 650. It is hard to know cause and
effect, because some infections are known to consume IgG, but lowrdiovascular Surgery c Volume 147, Number 2 813
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MIgG levels certainly seem to be a marker. If the IgG level is 800 to
1000 after surgery, the patient rarely gets this problem. It is related,
I think, to immune dysregulation contributed to in a major way by
cardiopulmonary bypass. With nosocomial infection sources,
immune depletion predisposes to the development of pulmonary
infection. I believe most of these patients have gram-negative noso-
comial pneumonias as their underlying problem.
I submitted an abstract 15 years ago saying that HITwas a major
factor in postoperative mortality because 25% of the patients who
died had thrombocytopenia syndrome, and I proposed that HIT
then caused pulmonary dysfunction, pulmonary infiltrates, and
multiorgan failure. Now, I am sure it is the other way around,
that it is mostly infection-related. If I go to Germany where they
maintain their operating room ventilators well, postoperative
pneumonia is unusual. It might help US centers if they studied
German infection control protocols.
Dr Katz. That is an interesting observation.
Dr Rankin. I do not have data on that; it is just my personal
impression.
Dr Katz. Yes, but an interesting observation.
Dr Rankin. Yes.
Dr Katz. My final question. In this era of cardiac surgery, it
certainly is not unusual to see platelet counts less than 60,000,
and there are 3 groups of patients, at least in our practice, that
I think I can identify in whom it is common. One group includes
patients who have undergone reoperative surgery and have a
coagulopathy postoperatively often related to perioperative
antiplatelet therapy. The second group includes patients who are
on ventricular assist devices and are undergoing extracorporeal
membrane oxygenation. The third group includes patients who
are being treated for sepsis postoperatively. On the basis of your
study, would you recommend that IVIG be used in these groups
of patients to decrease the need for platelet transfusions and
improve outcomes related to multiorgan system dysfunction?
Dr Rankin. Prophylactically?
Dr Katz. Well, if you see the platelet count go down.
Dr Rankin. Yes.
Dr Katz. To maybe not 60,000, but you are seeing it go down,
let’s say, to less than 100,000, and you have someone on a
ventricular assist device, do you think that it is appropriate to do
that, or would you interpret the platelet count going down because
of the system, the ventricular assist device or the extracorporeal
membrane oxygenation system?
Dr Rankin. I do not have experience with the population with
ventricular assist devices, and all the patients I reported today are
probably in your third category with infection as the cause. IVIG
works there, but I do not have experience with assist devices.
Certainly, there were patients in this series who experienced
bleeding postoperatively and had transfusions, which probably is
one risk factor, as we have discussed, but platelet counts were
all restored to normal before the pT developed.
Dr Harold Burkhart (Rochester, Minn). Did you look into IgG
levels before and after? Did you check that? I may have missed it.
Dr Rankin. Yes. Halfway through this series, around 2006, we
obtained the ability to get IgG levels after surgery. As I said, the
majority have low IgG levels immediately after surgery.
Dr GlennWhitman (Baltimore, Md). I thought I saw that there
were no positive cultures in this population, and yet I also thought I814 The Journal of Thoracic and Cardiovascular Surgheard you are attributing thrombocytopenia in this population to
Gram-negative septicemia. Could you explain the relationship
further?
Second, would you suggest that every patient who has
Gram-negative septicemia with thrombocytopenia be treated
with IVIG whether or not they had cardiac surgery?
Dr Rankin. Regarding your second question, infection-related
thrombocytopenia, from my interpretation of the literature, is an
on-label indication for IVIG at present, for example, Shiga toxin
cases. About your first question, I don’t think I said there were
no positive cultures. I said there were no patients with positive
PF4 antibodies. But our particular hospital has been a little
inconsistent with that test; we still have to send it to a remote
laboratory, so my confidence in the PF4 results is not perfect.
We were actually sending heparin-induced platelet aggregation
studies to Duke for Greenberg’s laboratory for a while, but again,
the majority were not positive. In fact, in most publications, it has
been unusual to have a positive PF4 in this population, usually with
less than one third of patients exhibiting PF4 positivity.
In our published series of immune dysfunction in the Journal in
2011, approximately one third of these patients had positive
pulmonary cultures, usually with Gram-negative rods, usually
multidrug resistant. As you know from the literature, it is difficult
to culture these kinds of organisms, with 30% to 40% positivity
being fairly standard around the world. I believe most of these
problems probably are related to postoperative pulmonary
infection of one sort or another.
Dr Lyle Joyce (Rochester, Minn). So are all patients candidates
or are there some patients who you would not treat?
Dr Rankin.Well, yes. Now, in a way, it is easier. I have stopped
ordering PF4s; up to 40% of patients eventually turn positive after
surgery anyway, so it is not a specific test. If the patient is 2 or 3
days postoperative, the IgG level is low, and the platelet count is
plummeting, I just start the IVIG protocol. It is very important
to complete the entire protocol (1.5 g/kg intravenously over 5
days) and not just a dose or 2. It seems clear to me that most of
the likely causes of pT are immune-mediated in one way or the
other, and they all seem to respond to IVIG in my series.
Dr Joyce. You will not wait for a negative hit, then?
Dr Rankin. Oh, no.
Dr Joyce. You just go ahead and get started?
Dr Rankin.Well, if it is a TTP-like antibody, as several articles
propose, it works there. If it is endotoxin, it works there. If it is a
PF4 antibody, IVIG is a standard therapy. The immune modulatory
effects of IVIG are effective in all those settings, and it has been
100% effective in our population.
Dr Joseph Rubelowsky (Hattiesburg, Miss). This is a fasci-
nating topic because I am dealing with this in exactly the same
population you are talking about with multivalves and patients
who develop renal failure. I round in the morning and say oh
my, the platelet count is low.
Now that I have this in my armamentarium, I never considered
this. But one thing I would be interested in is with my patient who
recently had a low platelet count and vancomycin-resistant
Enterococcus, and it was terrible. But I am always worried,
and like you said, this happens in valve cases. Then I have
transesophageal echocardiograms to show there were no
vegetations or paravalvular leaks.ery c February 2014
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out, are they coming back with paravalvular abscesses or infective
endocarditis, or do you keep them on long-term antibiotics just to
make sure that if they were septic, that we killed that bug and they
are not going to have a problem with that valve?
Dr Rankin. As we have written in our immune dysfunction
articles in the Journal and The Journal of Heart Valve Disease,
proper antibiotic coverage together with augmenting the immune
system are both important.The Journal of Thoracic and CaSo, it pays to obtain good bronchoalveolar cultures and use
good antibiotic protocols. I am sure that secondary endocarditis
can occur. I’ve had that happen in the remote past. But in this
series, once the patients got over the pulmonary infection and their
white blood counts returned to normal, the pT did not recur. I had 1
patient who required a second valve operation 1 week after
receiving IVIG for serious thrombocytopenia, and with the IVIG
on board, the thrombocytopenia did not recur. It looks to be an
effective therapy in the postsurgical setting.rdiovascular Surgery c Volume 147, Number 2 815
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